Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Author:

Frankel Arthur E.1,Woo Jung H.2,Ahn Chul1,Pemmaraju Naveen3,Medeiros Bruno C.4,Carraway Hetty E.5,Frankfurt Olga6,Forman Stephen J.7,Yang Xuezhong A.8,Konopleva Marina3,Garnache-Ottou Francine9,Angelot-Delettre Fanny9,Brooks Christopher10,Szarek Michael10,Rowinsky Eric10

Affiliation:

1. University of Texas Southwestern Medical Center, Dallas, TX;

2. Baylor Scott & White Health, Temple, TX;

3. The University of Texas MD Anderson Cancer Center, Houston, TX;

4. Stanford University School of Medicine, Stanford, CA;

5. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;

6. Northwestern University Feinberg School of Medicine, Chicago, IL;

7. City of Hope, Duarte, CA;

8. Bon Secours St. Francis Health Systems, Greenville, SC;

9. EFS Bourgogne Franche-Comte, INSERM UMR1098, EFS Bourgogne Franche-Comte, Besancon, France; and

10. Stemline Therapeutics, Inc., New York, NY

Abstract

Key PointsSL-401 was well tolerated, and a single course of treatment produced a high rate of objective responses in BPDCN patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3